Probiotic-3

C.butyricum TO-A is a natural resident of the human gastrointestinal tract. It breaks down dietary fiber into short-chain fatty acids (SCFAs); butyrate, propionate and acetate. The benefits of these SCFAs include reduced inflammation, protection against intestinal damage¹ thereby preventing “leaky gut” syndrome, improved insulin resistance and immune support.² E. faecium T-110 is a natural resident of the human gastrointestinal tract that works with C. butyricum to create a balanced microbiome. It produces lactic acid, which reduces the gastrointestinal pH, thus preventing the growth of harmful bacteria.³ It has also been shown to reduce the severity of acute diarrhea. B. subtilis TO-A is a prebiotic that supports the growth of E. faecium and C. butyricum, increasing their growth by 10 times.

Clinical studies have shown extensive health benefits, including allergy reduction,^4-6 improved immunity, reduced bloating, constipation and diarrhea, positive effects on cognition, depression, anxiety and even improved detoxification. What’s more, Probiotic-3 is the only probiotic product in Canada to contain a strain of bacteria from the Clostridium family, which has antagonistic effects against several pathogenic bacteria such as C. difficile, H. pylori and E. coli.

AOR Advantage

Probiotic-3’s unique symbiotic formula combines three human strains that have been clinically studied in over 40 human studies. It is stable at room temperature and highly resistant to bile and gastric acids. What’s more, this formula has 60 years of use in hospitals and pharmacies across Asia. Each strain has been carefully selected to ensure synergy and safety with the others.

References:

1. Glocker E-O, Kotlarz D, Boztug K, et al. Inflammatory Bowel Disease and Mutations Affecting the Interleukin-10 Receptor. N Engl J Med. 2009;361(21):2033-2045. doi:10.1056/NEJMoa0907206.
2. Hayashi A, Sato T, Kamada N, et al. A single strain of Clostridium butyricum induces intestinal IL-10-producing macrophages to suppress acute experimental colitis in mice. Cell Host Microbe. 2013;13(6):711-722. doi:10.1016/j.chom.2013.05.013.
3. Takahashi M, Taguchi H, Yamaguchi H, Osaki T, Kamiya S. Studies of the effect of Clostridium butyricum on Helicobacter pylori in several test models including gnotobiotic mice. J Med Microbiol. 2000;49(7):635-642. doi:10.1099/0022-1317-49-7-635.
4. Zhang J, Su H, Li Q, et al. Oral administration of Clostridium butyricum CGMCC0313-1 inhibits β-lactoglobulin-induced intestinal anaphylaxis in a mouse model of food allergy. Gut Pathog. 2017;9:11. doi:10.1186/s13099-017-0160-6.
5. Bin Lan B, Yang F, Lu D, Lin Z. Specific immunotherapy plus Clostridium butyricum alleviates ulcerative colitis in patients with food allergy. Sci Rep. 2016;6(1):25587. doi:10.1038/srep25587.
6. Cai M, Zeng L, Li L-J, et al. Specific immunotherapy ameliorates ulcerative colitis. Allergy, Asthma Clin Immunol. 2016;12(1):37. doi:10.1186/s13223-016-0142-0.

Label Information